Key Highlights
- Pulmatrix (NASDAQ:PULM) reported a third quarter net loss of USD 1.213 million, against USD 0.877 million a year earlier, or USD 0.34 a share after preferred dividends.
- General and administrative expense rose to USD 1.220 million from USD 0.858 million on Merger related legal and professional costs.
- Cash and cash equivalents were USD 1.4 million at September 30, 2026, plus USD 0.7 million of restricted cash, against USD 4.1 million at year end 2025.
- The merger with Eos SENOLYTIX is expected to close in November, subject to Nasdaq listing approval and a Reverse Stock Split approved by holders on October 26.
Merger Costs Widen the Quarterly Loss
Pulmatrix (NASDAQ:PULM) reported a net loss of USD 1,213 thousand for the third quarter ended September 30, 2026, compared with USD 877 thousand a year earlier. After USD 21 thousand of accrued Series B preferred dividends, the loss attributable to common stockholders was USD 1,234 thousand, or USD 0.34 a share against USD 0.24. General and administrative expense climbed to USD 1,220 thousand from USD 858 thousand, which the company ties to legal and professional services for the merger. Research and Development was only USD 1 thousand, since all clinical development is on hold. For nine months, net loss narrowed to USD 3,421 thousand from USD 4,234 thousand.
Cash Falls to USD 1.4 Million Ahead of the Eos Closing
Cash and cash equivalents were USD 1,398 thousand at September 30, 2026, down from USD 4,088 thousand at year end 2025. A further USD 700 thousand of restricted cash is released once the merger completes. Total Assets were USD 2,363 thousand against total liabilities of USD 1,017 thousand, leaving stockholders' Equity of USD 1,346 thousand, down from USD 3,810 thousand. Accumulated Deficit was USD 305,739 thousand. The company says its cash should cover operations at least through the expected merger closing, and that its financial statements assume it continues as a going concern.
Merger Conditions and Out-Licensing of Inhaled Assets
Interim Chief Executive Peter Ludlum says the company's focus has been on completing the transaction. Under the agreement signed March 26, 2026, a Subsidiary of Pulmatrix will merge into Eos SENOLYTIX, a private Houston company developing MitoXcel peptides for obesity, sarcopenia and other age related disorders. The registration statement became effective on September 25, 2026, and stockholders approved the deal. Closing still depends on Nasdaq approval of the new share listing and completion of the reverse stock split approved October 26, 2026. Meanwhile Pulmatrix is seeking to out-license or monetize its inhaled assets, including PUR3100 for acute migraine, which has an FDA study may proceed letter for a Phase 2 trial, and PUR1900, which partner Cipla plans to take into a Phase 3 trial in India with a 2% Royalty to Pulmatrix on sales outside the United States. Its iSPERSE dry powder technology, also licensed to MannKind and Cipla for certain fields, is covered by about 143 granted patents and 47 pending applications. At signing, an affiliate of Eos also bought Series B convertible preferred stock for USD 1.0 million of gross proceeds.
Where Things Stand
Pulmatrix is a company in transition: the quarter's higher spending was driven by merger related costs, cash fell to USD 1.4 million, and the clinical programs are on hold while it seeks to license them. Management expects cash to last through the Eos closing, targeted for November or the end of the year. Next markers are Nasdaq's approval of the listing, execution of the reverse split, the closing itself, and any deals for PUR3100 or PUR1900.






Please wait processing your request...